Study Summary
This trial evaluates if pre-treatment drugs reduce side effects when taking amivantamab and Lazertinib to treat cancer.
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 11 Secondary · Reporting Duration: Up to 14 months
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
Background Anti-cancer Therapy with Amivantamab Plus Lazertinib
1 of 1
Experimental Treatment
120 Total Participants · 1 Treatment Group
Primary Treatment: Background Anti-cancer Therapy with Amivantamab Plus Lazertinib · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Has the combination of amivantamab and lazertinib been endorsed by the Food & Drug Administration?
"The safety of Background Anti-cancer Therapy with Amivantamab Plus Lazertinib is estimated to be a 2, as this is part of Phase 2 clinical trials and there are some data points that confirm its security but none which prove its efficacy." - Anonymous Online Contributor
Are there any vacancies yet for participants in this research study?
"Clinicaltrials.gov shows that this trial, which was posted on April 9th 2023 and last updated January 31st of the same year, is not currently recruiting patients. Nevertheless, at present there are 1,319 other clinical trials actively searching for volunteers to take part in their research projects." - Anonymous Online Contributor